Cells hold countless possibilities.
We will explore these possibilities through science, and translate them into the lives of patients all over the world.
Metcela’s core patented technology involves a particular population of cardiac fibroblasts, namely VCAM-1-positive cardiac fibroblast (VCF)*. VCAM-1-positive cardiac fibroblasts are known to replenish and re-establish the damaged cardiac muscles and the microenvironment surrounding them.
By using the patients’ own cells, we are aiming to provide an effective and efficient alternative therapies to patients of heart failure.
*Patent granted in Japan (No.6241893), Europe and China, and is currently pending in the U.S.